Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
260.00    0.00 (0.00%)
Bid:
256.00
Ask:
265.00
Spread: 9.00 (3.516%)
Market Cap: £232.84m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Trading Statement

23 Jul 2025 07:00

RNS Number : 1038S
Wilmington PLC
23 July 2025
 

23 July 2025

Wilmington plc

 

Year-end trading update

 

Wilmington plc, (LSE: WIL, 'Wilmington', 'the Group') the provider of data, information, education and training in the global Governance, Risk and Compliance ('GRC') markets, today provides a trading update for the year ended 30 June 2025.

 

Revenue growth from the Group's ongoing* businesses is expected to be 11%, led by both recent acquisitions in the HSE sector delivering double-digit percentage growth.

 

As at the half year, seven out of nine businesses grew year on year. Following the portfolio changes last year of two disposals and two acquisitions, and the continuing disruption in the US healthcare insurance market impacting our US events business over a full year, reported revenue is expected to be £101.5m (2024: £126m), with organic** revenue also having decreased 1% due to the US.

 

Operating profit from ongoing* businesses is expected to be up 11%, adjusted*** profit before tax is expected to be £27.7m (2024: £27.6m), with adjusted PBT margin up to 27% (2024: 22%).

 

Cash conversion continued to be strong at 107% of profits, with Group net cash on 30 June 2025 at £41.9m (30 June 2024: £67.8m) after the completion of the acquisition of Phoenix Health & Safety on 25 October 2024 and spending £3.4m on share buybacks.

 

Wilmington expects to publish its year end results on 22 September 2025.

 

Mark Milner, Chief Executive Officer, commented:

 

"We have seen another year of good ongoing* revenue and profit growth with both measures increasing 11%, reflecting our focus on a slimmed down higher quality portfolio of growing businesses. Margins have also continued to improve and both of our recent acquisitions have seen double digit growth. This performance came against a tough macro backdrop, particularly in the US healthcare market which has seen continued disruption in the course of our H2.

 

"With the acquisition of Phoenix, we have continued to actively manage our portfolio of businesses and are pursuing various opportunities to invest our cash in acquisitions to improve the quality of revenue and profits."

 

*Ongoing - eliminating the effects of the impact of disposals, closures and businesses held for sale.

**Organic - Ongoing, eliminating acquisitions and exchange rate fluctuations

***Adjusted profit before tax (PBT) is calculated as PBT after adding back amortisation and impairment of intangible assets (except computer software) and profits/losses on disposals and business closures. Market consensus adjusted profit before tax is £27.0m.

 

For further information, please contact:

 

Wilmington plc

Mark Milner, Chief Executive Officer

Guy Millward, Chief Financial Officer

 

Meare Consulting

Adrian Duffield

 

 

020 7490 0049

 

 

 

 

07990 858548

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for data, information, education and training in the global Governance, Risk and Compliance (GRC) markets. Wilmington employs around 600 people and sells to around 120 countries. Wilmington is listed on the main market of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUUUORVWUBUAR
Date   Source Headline
4th Mar 20257:00 amRNSTransaction in Own Shares
3rd Mar 20254:39 pmRNSDirector/PDMR Shareholding
3rd Mar 20254:35 pmRNSDirector/PDMR Shareholding
3rd Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20257:00 amRNSTransaction in Own Shares
27th Feb 20257:00 amRNSShare repurchase programme
17th Feb 20257:00 amRNSHalf-year Report
17th Jan 20259:42 amRNSNotice of Half Year Results
4th Dec 20247:00 amRNSDirector/PDMR Shareholding
28th Nov 202411:03 amRNSResult of AGM
25th Nov 20241:37 pmRNSHolding(s) in Company
20th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20243:13 pmRNSDirector/PDMR Shareholding
1st Nov 20247:00 amRNSTotal Voting Rights
25th Oct 20247:00 amRNSAcquisition of Phoenix Health & Safety
21st Oct 20241:47 pmRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSIssue of Ordinary Shares
1st Oct 20247:00 amRNSDirector/PDMR Shareholding
16th Sep 20247:00 amRNSFinancial results for the year ended 30 June 2024
2nd Sep 20247:00 amRNSTotal Voting Rights
29th Jul 20248:59 amRNSDirector Declaration
24th Jul 20247:00 amRNSTrading Statement
10th Jul 202410:57 amRNSHolding(s) in Company
2nd Jul 20242:51 pmRNSTotal Voting Rights - Replacement
1st Jul 20247:00 amRNSTotal Voting Rights
27th Jun 20247:00 amRNSUK Healthcare Business sold for £26.3 million
26th Apr 20247:46 amRNSAPM sold for EUR 26 million
23rd Apr 20243:49 pmRNSSAYE and Director/PDMR Shareholding
19th Feb 20247:00 amRNSHalf-year Report
6th Feb 202411:12 amRNSBoard Changes
1st Feb 20247:00 amRNSMiExact sold for £9.6 million
18th Jan 202411:00 amRNSNotice of Half Year Results
2nd Jan 20247:00 amRNSTotal Voting Rights
18th Dec 20232:42 pmRNSIssue of ordinary shares
11th Dec 20233:54 pmRNSIssue of Ordinary Shares
7th Dec 20232:25 pmRNSIssue of Ordinary Shares
1st Dec 202311:40 amRNSDirector/PDMR Shareholding
30th Nov 20232:53 pmRNSIssue of Ordinary Shares
23rd Nov 20239:49 amRNSAcquisition of Astutis Ltd by Wilmington plc
22nd Nov 20232:37 pmRNSResult of AGM
1st Nov 20237:00 amRNSTotal Voting Rights
3rd Oct 20232:52 pmRNSHolding(s) in Company
2nd Oct 202311:57 amRNSDirector/PDMR Shareholding
2nd Oct 202310:19 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSIssue of Ordinary Shares
25th Sep 20236:06 pmRNSAmendment to Financial Results announcement
25th Sep 20237:00 amRNSFinancial results for the year ended 30 June 2023
26th Jul 20237:00 amRNSTrading Statement
11th Apr 20237:00 amRNSSAYE and Director/PDMR Shareholding
7th Mar 20235:32 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.